Jam

BioAge Labs presents preclinical data demonstrating apelin receptor (APJ) agonist potential for diabetic obesity and heart failure with preserved ejection fraction (HFpEF). APJ activation, acting as an exercise mimetic, enhances the effects of incretin therapy, improving glycemic control and offering cardioprotective benefits. The company is developing next-generation APJ agonists, including oral and injectable formulations, with an IND filing planned for 2026, aiming to develop new therapies for obesity and its complications.

Eli Lilly announced positive Phase 3 results for orforglipron, a once-daily oral drug for type 2 diabetes. The ACHIEVE-1 trial showed the drug lowered A1C levels (1.3-1.6% reduction) in four weeks and promoted weight loss (up to 7.9%). The safety profile was consistent with existing GLP-1 medications. Lilly plans further studies, positioning orforglipron as a potential competitor in the diabetes and weight-loss treatment market.

At SNMMI, GE HealthCare unveils theranostics-enabling solutions focused on precision care. The debut of MIM Software’s LesionID Pro utilizes AI for automated pre-processing, streamlining workflows and aiding in personalized cancer treatment. Key highlights include the MINItrace Magni cyclotron, the Omni Legend PET/CT, and the StarGuide SPECT/CT, facilitating improved disease detection, treatment accuracy and efficient workflow. GE HealthCare aims to provide comprehensive solutions, from imaging to software, advancing personalized medicine and improving patient outcomes.

WhiteHawk Income Corporation’s tender offer for PHX Minerals Inc. has been largely accepted, with approximately 73.8% of PHX shares tendered. The acquisition is set to finalize on June 23, 2025. WhiteHawk, focused on acquiring mineral interests in key natural gas plays, will acquire PHX. The deal is subject to risk, including integration issues.

SINOVAC Biotech Ltd. successfully defended against a legal challenge in New York, paving the way for its declared $55.00 per share dividend. The court denied Advantech/Prime’s petition, a move that supports the current board’s actions and their plans for further shareholder payouts. Shareholders are encouraged to vote against proposals to oust the current board.

DDB Worldwide, part of Omnicom, was named Network of the Year at the 2025 Cannes Lions, marking its second win in three years. Under the leadership of Alex Lubar and Chaka Sobhani, DDB collected 112 Lions, including four Grands Prix. Key highlights include regional wins, agency awards, and record-breaking achievements for DDB Latina. DDB’s success, driven by impactful creativity, is a testament to its “emotional advantage” approach.

University Bancorp (UNIB) increased its stake in Currency Exchange International (CXI) by approximately 0.48%, reaching about 12.02% ownership. The company acquired shares on both the Toronto Stock Exchange and the OTC Markets. UNIB views its CXI holdings as an investment, subject to ongoing review, and may consider various strategic options. The announcement follows UNIB’s strong 2024 financial results and highlights its position as a significant financial holding company in Michigan.

InnSuites Hospitality Trust (IHT) reported a strong Q1 2026 with over $2 million in hotel revenue and $2.2 million total revenue. The company is diversifying through investments in clean energy (UniGen Power) and managing InnDependent Boutique Collection (IBC Hotels). IHT maintains a positive outlook, citing strong hotel performance, potential in diversification, and commitment to annual dividends. The annual shareholder meeting is scheduled for August 14, 2025.

Lipella Pharmaceuticals Inc. is delisted from the Nasdaq Capital Market due to rule violations regarding private placement transactions. The delisting, involving the issuance of convertible preferred stock and warrants, led to the suspension of trading. While disappointed, the company is exploring alternative markets, remains focused on its clinical development plans for LP-10 and LP-310, and is pressing forward with its mission to address unmet medical needs.

Halozyme Therapeutics announced the European Commission’s approval of argenx’s VYVGART subcutaneous injection, utilizing Halozyme’s ENHANZE drug delivery technology, for chronic inflammatory demyelinating polyneuropathy (CIDP). This approval, based on positive ADHERE trial data, marks a significant advancement for CIDP treatment and expands drug access across Europe. VYVGART, the first targeted IgG Fc-antibody fragment for CIDP, represents a new treatment mechanism in over three decades. The SC injection can be administered by patients, caregivers, or healthcare professionals.